LexaGene Holdings Inc. (LXXGF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
LexaGene Holdings Inc. (LXXGF) trades at $0.08 with AI Score 53/100 (Grade B). LexaGene Holdings Inc. is a biotechnology company focused on developing and commercializing pathogen detection systems. Market cap: $11.34M, Sector: Healthcare.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for LXXGF: LXXGF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates LXXGF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
LXXGF: 2/4 perspectives are bullish. Dominant signal: Jim Simons bearish.
How is this calculated? →LexaGene Holdings Inc. (LXXGF) Healthcare & Pipeline Overview
LexaGene Holdings Inc. is a biotechnology firm specializing in pathogen detection systems, notably MiQLab, targeting veterinary, clinical, and food safety markets. With a focus on on-site sample analysis, LexaGene aims to offer rapid and broad pathogen detection, differentiating itself through ease-of-use and sensitivity in a competitive medical devices landscape.
What Is the Investment Thesis for LXXGF?
LexaGene Holdings Inc. presents a speculative investment opportunity within the pathogen detection market. The company's MiQLab system targets multiple sectors, including veterinary and human diagnostics. A key value driver is the potential for MiQLab to disrupt traditional lab testing by offering rapid, on-site results. However, the company's negative profit margin of -14101.0% and gross margin of -621.4% indicate significant challenges in achieving profitability. Upcoming catalysts include potential partnerships and regulatory approvals for expanded applications of MiQLab. Investors should carefully consider the high beta of 2.04, indicating significant volatility, and the risks associated with OTC-traded companies.
Based on FMP financials and quantitative analysis
LXXGF Key Highlights
- Market capitalization of $11.34M reflects its small size and speculative nature.
- P/E ratio of -0.91 indicates the company is currently not profitable.
- Profit margin of -14101.0% highlights significant challenges in achieving profitability.
- Gross margin of -621.4% indicates that the cost of goods sold is substantially higher than revenue.
- Beta of 2.04 suggests high volatility compared to the overall market.
Who Are LXXGF's Competitors?
LXXGF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ATBPF Antibe Therapeutics Inc. | $0.22 | -0.19% | $11.43M | 44 |
| CDXFF Cloud DX Inc. | $0.09 | +12.50% | $9.75M | 54 |
| CNPOF RIV Capital Inc. | $0.08 | +0.00% | $10.96M | 36 |
| EIGRQ Eiger BioPharmaceuticals, Inc. | $8.50 | +6.25% | $12.59M | 54 |
| DCTH Delcath Systems, Inc. | $13.61 | +3.11% | $469.84M | 73 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.20 | +3.40% | $18.68M | 73 |
| SSII SS Innovations International, Inc. | $3.76 | -0.53% | $752.49M | 72 |
| RSHUF Respiri Limited | $0.06 | +0.00% | $91.52M | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are LXXGF's Key Strengths?
- Innovative MiQLab technology.
- On-site pathogen detection capabilities.
- Potential for rapid results.
- Broad application across multiple sectors.
What Are LXXGF's Weaknesses?
- Negative profit and gross margins.
- Limited market presence.
- Reliance on a single product.
- High beta indicating volatility.
What Could Drive LXXGF Stock Higher?
- Potential partnerships with veterinary clinics to expand MiQLab adoption.
- Regulatory approvals for MiQLab in human clinical diagnostics.
- Development of new diagnostic panels for MiQLab.
- Expansion of sales and marketing efforts to increase market awareness.
- Research and development of next-generation pathogen detection technologies.
What Are the Key Risks for LXXGF?
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Competition from established players in the diagnostics industry.
- Regulatory hurdles and delays in obtaining approvals.
- Negative profit and gross margins.
- Limited market presence and brand recognition.
- Reliance on a single product (MiQLab).
What Are the Growth Opportunities for LXXGF?
- Expansion into Veterinary Diagnostics: The veterinary diagnostics market represents a significant growth opportunity for LexaGene. With increasing pet ownership and rising awareness of animal health, the demand for rapid and accurate pathogen detection in veterinary clinics is growing. MiQLab's ease of use and on-site capabilities position it well to capture a share of this market, estimated to reach billions of dollars in the coming years. Success in this area could significantly boost revenue and establish LexaGene as a key player in veterinary diagnostics.
- Penetration of Human Clinical Diagnostics: The human clinical diagnostics market offers substantial growth potential for LexaGene. Rapid and accurate pathogen detection is critical for diagnosing and treating infectious diseases. MiQLab's ability to provide on-site results could be particularly valuable in emergency rooms and urgent care centers. Securing regulatory approvals and partnerships with healthcare providers are crucial steps for penetrating this market, which is projected to experience continued growth due to aging populations and increasing prevalence of infectious diseases.
- Adoption in Food and Water Safety Testing: The food and water safety testing market is driven by stringent regulations and increasing consumer awareness of foodborne illnesses. MiQLab's pathogen detection capabilities can be applied to detect contaminants in food and water samples, ensuring compliance with safety standards. Collaborating with food processing companies and water treatment facilities can provide LexaGene with access to this market, which is expected to grow as food safety regulations become more stringent globally.
- Development of New Diagnostic Panels: Expanding the range of pathogens that MiQLab can detect through the development of new diagnostic panels represents a key growth opportunity. By continuously adding new panels, LexaGene can enhance the value proposition of its system and attract a wider range of customers. This requires ongoing research and development efforts, as well as strategic partnerships with research institutions and diagnostic companies. The ability to rapidly adapt to emerging pathogens will be a critical factor in maintaining a competitive edge.
- Strategic Partnerships and Distribution Agreements: Forming strategic partnerships with established players in the diagnostics and life sciences industries can accelerate LexaGene's market penetration. These partnerships can provide access to distribution networks, marketing resources, and technical expertise. Collaborating with companies that have complementary technologies can also lead to the development of integrated solutions that offer greater value to customers. Successful partnerships can significantly expand LexaGene's reach and accelerate its growth trajectory.
What Opportunities Does LXXGF Have?
- Expansion into veterinary diagnostics.
- Penetration of human clinical diagnostics.
- Adoption in food and water safety testing.
- Development of new diagnostic panels.
What Threats Does LXXGF Face?
- Competition from established players.
- Regulatory hurdles.
- Technological obsolescence.
- Economic downturn affecting healthcare spending.
What Are LXXGF's Competitive Advantages?
- Proprietary MiQLab technology.
- Ease-of-use and on-site capabilities.
- Broad spectrum of pathogen detection.
- Potential for network effects as more diagnostic panels are developed.
What Does LXXGF Do?
LexaGene Holdings Inc., established in 2007 and headquartered in Beverly, Massachusetts, is a biotechnology company dedicated to the research, development, and commercialization of advanced pathogen detection systems. The company's flagship product, MiQLab, is an automated system designed to transform pathogen detection across various sectors, including veterinary diagnostics, human clinical diagnostics, food and water safety testing, and other life sciences markets. MiQLab is engineered for use at the point of sample collection, offering ease-of-use, high sensitivity, and a broad spectrum of pathogen detection capabilities. LexaGene's focus is on providing rapid and accurate results, enabling quicker response times in critical areas such as disease control and food safety. The company aims to address the limitations of traditional laboratory-based testing methods by offering a decentralized, user-friendly solution. By targeting multiple sectors, LexaGene seeks to diversify its revenue streams and mitigate risks associated with reliance on a single market. The company's innovative approach positions it to capitalize on the growing demand for rapid and accurate pathogen detection technologies in a variety of industries.
What Products and Services Does LXXGF Offer?
- Develops and commercializes pathogen detection systems.
- Offers MiQLab, an automated pathogen detection platform.
- Targets veterinary diagnostics market.
- Aims to transform human clinical diagnostics.
- Provides solutions for food and water safety testing.
- Focuses on on-site sample analysis for rapid results.
- Offers ease-of-use, sensitivity, and breadth of pathogen detection.
How Does LXXGF Make Money?
- Sales of MiQLab pathogen detection systems.
- Revenue from diagnostic panels and consumables.
- Service and maintenance contracts for MiQLab systems.
- Potential licensing agreements for its technology.
What Industry Does LXXGF Operate In?
LexaGene Holdings Inc. operates in the medical device industry, specifically within the pathogen detection segment. This market is driven by increasing concerns about food safety, disease outbreaks, and the need for rapid diagnostics. The competitive landscape includes companies like ATBPF (Alliance Bio Products Inc.), AVEFF (Avellino Lbm Inc), CDXFF (CareDx Inc), CNPOF (Canna-Pet Advanced Formulas Corp), and EIGRQ (Bio-Rad Laboratories Inc), some of which offer competing pathogen detection technologies. The industry is characterized by technological innovation, regulatory scrutiny, and the need for cost-effective solutions. LexaGene aims to differentiate itself through its MiQLab system's ease of use and broad detection capabilities.
Who Are LXXGF's Key Customers?
- Veterinary clinics and hospitals.
- Human clinical diagnostic laboratories.
- Food processing companies.
- Water treatment facilities.
How LexaGene Holdings Inc. Is Valued
Relative to its peer group, LXXGF's quantitative score of 53/100 is roughly in line with the peer average of 52/100.
Company Profile
LexaGene Holdings Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Beverly, US. The company is led by CEO John F. Regan.
F-Score 3/9Financial Health
LexaGene Holdings Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
LXXGF Financials
Bull Case vs Bear Case
Bull Case
- Innovative MiQLab technology.
- On-site pathogen detection capabilities.
- Potential for rapid results.
- Broad application across multiple sectors.
Bear Case
- Negative profit and gross margins.
- Limited market presence.
- Reliance on a single product.
- High beta indicating volatility.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
LXXGF Latest News
No recent news available for LXXGF.
LXXGF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for LXXGF.
Price Targets
Wall Street price target analysis for LXXGF.
LXXGF MoonshotScore
What does this score mean?
The MoonshotScore rates LXXGF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: John F. Regan
CEO
John F. Regan serves as the CEO of LexaGene Holdings Inc. His leadership is pivotal in guiding the company's strategic direction and overseeing the development and commercialization of its pathogen detection systems. He is responsible for managing the company's 33 employees and driving its growth initiatives. His background includes experience in the biotechnology and diagnostics industries.
Track Record: Under John F. Regan's leadership, LexaGene has focused on advancing its MiQLab technology and expanding its applications across various sectors. Key milestones include securing partnerships, obtaining regulatory approvals, and driving market adoption of MiQLab. His strategic decisions have been instrumental in positioning LexaGene as an innovator in the pathogen detection market.
LXXGF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that LexaGene Holdings Inc. may not meet the minimum financial or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. This tier often includes companies with distressed financials, early-stage ventures, or those that choose not to meet the listing requirements of higher tiers.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited liquidity and trading volume.
- Less stringent regulatory oversight.
- Potential for price manipulation.
- Higher risk of financial distress or bankruptcy.
- Limited access to company information.
- Verify the company's financial statements and SEC filings (if available).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent portfolio.
- Review the company's legal and regulatory compliance.
- Monitor news and press releases for any red flags.
- Consult with a financial advisor before investing.
- Company has been in operation since 2007.
- Focus on developing and commercializing pathogen detection systems.
- MiQLab technology targets multiple sectors.
- CEO John F. Regan has experience in the biotechnology industry.
LexaGene Holdings Inc. Healthcare Stock: Key Questions Answered
What does LexaGene Holdings Inc. do?
LexaGene Holdings Inc. is a biotechnology company focused on developing and commercializing pathogen detection systems. Its primary product, MiQLab, is an automated platform designed for rapid and accurate pathogen detection across various sectors, including veterinary diagnostics, human clinical diagnostics, and food and water safety testing. The company aims to provide on-site solutions that offer ease-of-use, sensitivity, and a broad range of pathogen detection capabilities, differentiating itself from traditional laboratory-based testing methods.
What do analysts say about LXXGF stock?
As of 2026-03-18, there is no readily available analyst consensus on LXXGF stock due to its OTC listing and small market capitalization. Key valuation metrics such as P/E ratio (-0.91) and profit margin (-14101.0%) suggest the company is currently not profitable. Growth considerations revolve around the successful commercialization of MiQLab and expansion into new markets. Investors should conduct thorough due diligence and consider the risks associated with OTC-traded companies.
What are the main risks for LXXGF?
The main risks for LexaGene Holdings Inc. include its negative profit and gross margins, indicating challenges in achieving profitability. Competition from established players in the diagnostics industry poses a threat to market share. Regulatory hurdles and delays in obtaining approvals for MiQLab could impede growth. As an OTC-traded company, LXXGF faces risks associated with limited liquidity, less stringent regulatory oversight, and potential price volatility. Reliance on a single product (MiQLab) also presents a concentration risk.
What are the key factors to evaluate for LXXGF?
LexaGene Holdings Inc. (LXXGF) holds an AI score of 53/100 (moderate). Not financial advice.
How frequently does LXXGF data refresh on this page?
LXXGF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven LXXGF's recent stock price performance?
LexaGene Holdings Inc. (LXXGF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative MiQLab technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider LXXGF overvalued or undervalued right now?
Valuing LexaGene Holdings Inc. (LXXGF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying LXXGF?
Before investing in LexaGene Holdings Inc. (LXXGF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- OTC data may be less reliable than exchange-listed data.
- Financial data is limited and may not be up-to-date.